The Year in Cardiology 2013: Cardiovascular disease prevention

European Heart Journal

Volumn 35, Issue 5, 2014, Pages 307-312

  Gielen, S ^a   Landmesser, U ^b  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cardiovascular disease prevention; Epidemiology; Heart rate; Intervention; Lifestyle

Indexed keywords

CARDIOVASCULAR DISEASE PREVENTION; EPIDEMIOLOGY; HEART RATE; INTERVENTION; LIFESTYLE;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS; EPIDEMIOLOGIC METHODS; EXERCISE THERAPY; FEMALE; FORECASTING; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; OBESITY; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 84893872136     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht551     Document Type: Review

References (26)

1. Nichols M, TownsendN, Scarborough P, Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J 2013;34:3017-3027.
2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: Epidemiological update. Eur Heart J 2013;34:3028-3034.
3. Jørgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T,De Bacquer D, de Sutter J, Franco OH, Løgstrup S, Volpe M, Malyutina S, Marques-Vidal P, Reiner Z, Tell GS, Verschuren WMM, Vanuzzo D. PEP Section of EACPR. Population-level changes to promote cardiovascular health. Eur J Prev Cardiol 2013;20:409-421.
4. European Cardiovascular Disease Statistics 2012 edition [Internet] [cited 2013 Oct 23]. http://www.escardio.org/about/Documents/EU-cardiovasculardisease- statistics-2012.pdf (Accessed 11 December 2013).
5. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L,Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, ZatonskiW, Rosengren A, Teo KK., Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011;378:1231-1243.
6. ChowCK, Teo KK, Rangarajan S, Islam S, GuptaR,Avezum A, Bahonar A,Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE (Prospective Urban Rural Epidemiology) Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA J Am Med Assoc 2013;310:959-968.
7. Teo K, Lear S, Islam S, Mony P, Dehghan M, LiW, Rosengren A, Lopez-Jaramillo P, Diaz R, Oliveira G, Miskan M, Rangarajan S, Iqbal R, Ilow R, Puone T, Bahonar A, Gulec S, Darwish EA, Lanas F, Vijaykumar K, Rahman O, Chifamba J, Hou Y, Li N, Yusuf S, PURE Investigators. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA J Am Med Assoc 2013;309: 1613-1621.
8. King DE, Mainous AG, Matheson EM, Everett CJ. Impact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive protein. Eur J Prev Cardiol 2013;20:73-79.
9. Plichart M, Thomas F, Empana J-P, Bean K, Périer M-C, Celermajer DS, Hanon O, Danchin N, Pannier B, Jouven X. Gender-specific trends in heart rate in the general population from 1992-2007: A study of 226,288 French adults. Eur J Prev Cardiol 2013;20:61-72.
10. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: Subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013;381:537-545.
11. Krum H, Schlaich MP, BöhmM, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2013; doi: 10.1016/S0140- 6736(13)62192-3
12. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
13. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-Analysis of individual data from 27 randomised trials. Lancet 2012;380:581-590.
14. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
15. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, for the VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 Randomized Clinical Trial. JAMA 2013. doi: 10.1001/jama.2013.282836.
16. Lüscher TF, Taddei S, Kaski J-C, Jukema JW, Kallend D, Münzel T, Kastelein JJP, Deanfield JE, dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857-865.
17. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, dal-OUTCOMESInvestigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367: 2089-2099.
18. Landmesser U. The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: The re-emergence and fall of niacin. Eur Heart J 2013;34: 1254-1257.
19. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2013 [Epub ahead of print].
20. Global Lipids Genetics Consortium, discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-1283.
21. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuireDK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.
22. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med 2013;369:1327-1335.
23. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154.
24. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-Analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
25. Schmid J-P, Zurek M, Saner H. Chronotropic incompetence predicts impaired response to exercise training in heart failure patients with sinus rhythm. Eur J Prev Cardiol 2013;20:585-592.
26. Smith SC Jr, Collins A, Ferrari R, Holmes DR Jr, Logstrup S, McGhie DV, Ralston J, Sacco RL, Stam H, Taubert K, Wood DA, Zoghbi WA, World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, European Society of Cardiology. Our time: A call to save preventable death from cardiovascular disease (heart disease and stroke). Eur Heart J 2012;33:2910-2916.